Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb:73:103667.
doi: 10.1016/j.breast.2023.103667. Epub 2023 Dec 22.

Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data

Yasmine Rhanine  1 , Hervé Bonnefoi  2 , Anthony Goncalves  3 , Marc Debled  1 , Sylvestre Le Moulec  4 , Nathalie Bonichon  5 , Gaetan Macgrogan  6 , Monica Arnedos  1 , Bénédicte Dubroca-Dehez  7 , Thomas Grellety  8
Affiliations

Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data

Yasmine Rhanine et al. Breast. 2024 Feb.

Abstract

Antiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life. The primary end-point was CBR at 6 months. Twenty-four patients were assessable and received: abiraterone acetate (62 %), enzalutamide (8 %) and bicalutamide (30 %). CBR at 6 months was 29 % (7/24) with 2 CR, 3 PR and 2 SD. Four patients had a clinical benefit >12 months. Real-life efficacy of AA use in metastatic AR + TNBC are in line with data from published trials.

Keywords: Androgen receptor; Androgen receptor-positive triple-negative breast cancer; Antiandrogens; Biomarker; Clinical benefit rate; Real-life data.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest All authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Representation of the IHC4 apocrine scores and AR staining. Patients with clinical benefit were those achieving a 6-month CBR. Black bars represent the median.
See this image and copyright information in PMC

References

    1. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–2767. - PMC - PubMed
    1. Burstein M.D., Tsimelzon A., Poage G.M., et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21:1688–1698. - PMC - PubMed
    1. Bareche Y., Venet D., Ignatiadis M., Aftimos P., Piccart M., Rothe F., et al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol. 2018;29:895. - PMC - PubMed
    1. Farmer P., Bonnefoi H., Becette V., Tubiana-Hulin M., Fumoleau P., Larsimont D., et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24:4660–4671. - PubMed
    1. Doane A.S., Danso M., Lal P., Donaton M., Zhang L., Hudis C., et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006;25:3994–4008. - PubMed

MeSH terms